vs
Side-by-side financial comparison of Nextpower Inc. (NXT) and Insulet Corporation (PODD). Click either name above to swap in a different company.
Nextpower Inc. is the larger business by last-quarter revenue ($909.4M vs $783.7M, roughly 1.2× Insulet Corporation). Nextpower Inc. runs the higher net margin — 14.4% vs 13.0%, a 1.5% gap on every dollar of revenue. On growth, Nextpower Inc. posted the faster year-over-year revenue change (33.9% vs 31.2%). Nextpower Inc. produced more free cash flow last quarter ($118.5M vs $48.2M). Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs 11.1%).
Nextpower Inc. (NXT) is a global energy technology provider based in Fremont, California.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
NXT vs PODD — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $909.4M | $783.7M |
| Net Profit | $131.2M | $101.6M |
| Gross Margin | 31.7% | 72.6% |
| Operating Margin | 19.4% | 18.7% |
| Net Margin | 14.4% | 13.0% |
| Revenue YoY | 33.9% | 31.2% |
| Net Profit YoY | 13.8% | 0.9% |
| EPS (diluted) | $0.85 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $909.4M | $783.7M | ||
| Q3 25 | $905.3M | $706.3M | ||
| Q2 25 | $864.3M | $649.1M | ||
| Q1 25 | $924.3M | $569.0M | ||
| Q4 24 | $679.4M | $597.5M | ||
| Q3 24 | $635.6M | $543.9M | ||
| Q2 24 | $719.9M | $488.5M | ||
| Q1 24 | $736.5M | $441.7M |
| Q4 25 | $131.2M | $101.6M | ||
| Q3 25 | $146.9M | $87.6M | ||
| Q2 25 | $157.2M | $22.5M | ||
| Q1 25 | $156.8M | $35.4M | ||
| Q4 24 | $115.3M | $100.7M | ||
| Q3 24 | $115.4M | $77.5M | ||
| Q2 24 | $121.7M | $188.6M | ||
| Q1 24 | $205.2M | $51.5M |
| Q4 25 | 31.7% | 72.6% | ||
| Q3 25 | 32.4% | 72.2% | ||
| Q2 25 | 32.6% | 69.7% | ||
| Q1 25 | 33.1% | 71.9% | ||
| Q4 24 | 35.5% | 72.1% | ||
| Q3 24 | 35.4% | 69.3% | ||
| Q2 24 | 33.0% | 67.7% | ||
| Q1 24 | 46.2% | 69.5% |
| Q4 25 | 19.4% | 18.7% | ||
| Q3 25 | 20.0% | 16.7% | ||
| Q2 25 | 21.5% | 18.7% | ||
| Q1 25 | 21.1% | 15.6% | ||
| Q4 24 | 22.1% | 18.3% | ||
| Q3 24 | 21.0% | 16.2% | ||
| Q2 24 | 22.2% | 11.2% | ||
| Q1 24 | 36.8% | 12.9% |
| Q4 25 | 14.4% | 13.0% | ||
| Q3 25 | 16.2% | 12.4% | ||
| Q2 25 | 18.2% | 3.5% | ||
| Q1 25 | 17.0% | 6.2% | ||
| Q4 24 | 17.0% | 16.9% | ||
| Q3 24 | 18.2% | 14.2% | ||
| Q2 24 | 16.9% | 38.6% | ||
| Q1 24 | 27.9% | 11.7% |
| Q4 25 | $0.85 | $1.42 | ||
| Q3 25 | $0.97 | $1.24 | ||
| Q2 25 | $1.04 | $0.32 | ||
| Q1 25 | $1.05 | $0.50 | ||
| Q4 24 | $0.79 | $1.38 | ||
| Q3 24 | $0.79 | $1.08 | ||
| Q2 24 | $0.84 | $2.59 | ||
| Q1 24 | $1.52 | $0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $952.6M | — |
| Total DebtLower is stronger | — | $930.8M |
| Stockholders' EquityBook value | $2.2B | $1.5B |
| Total Assets | $3.8B | $3.2B |
| Debt / EquityLower = less leverage | — | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $952.6M | — | ||
| Q3 25 | $845.3M | — | ||
| Q2 25 | $743.4M | — | ||
| Q1 25 | $766.1M | — | ||
| Q4 24 | $693.5M | — | ||
| Q3 24 | $561.9M | — | ||
| Q2 24 | $471.9M | — | ||
| Q1 24 | $474.1M | — |
| Q4 25 | — | $930.8M | ||
| Q3 25 | — | $934.9M | ||
| Q2 25 | — | $939.0M | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B | ||
| Q1 24 | — | $1.4B |
| Q4 25 | $2.2B | $1.5B | ||
| Q3 25 | $2.0B | $1.4B | ||
| Q2 25 | $1.8B | $1.5B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.4B | $1.2B | ||
| Q3 24 | $1.3B | $1.1B | ||
| Q2 24 | $1.1B | $998.4M | ||
| Q1 24 | $961.0M | $790.7M |
| Q4 25 | $3.8B | $3.2B | ||
| Q3 25 | $3.7B | $3.0B | ||
| Q2 25 | $3.4B | $3.5B | ||
| Q1 25 | $3.2B | $3.5B | ||
| Q4 24 | $3.0B | $3.1B | ||
| Q3 24 | $2.8B | $3.0B | ||
| Q2 24 | $2.6B | $2.9B | ||
| Q1 24 | $2.5B | $2.6B |
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.68× | ||
| Q2 25 | — | 0.64× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | 1.21× | ||
| Q2 24 | — | 1.36× | ||
| Q1 24 | — | 1.72× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $123.3M | $183.3M |
| Free Cash FlowOCF − Capex | $118.5M | $48.2M |
| FCF MarginFCF / Revenue | 13.0% | 6.2% |
| Capex IntensityCapex / Revenue | 0.5% | 17.2% |
| Cash ConversionOCF / Net Profit | 0.94× | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | $587.3M | $377.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $123.3M | $183.3M | ||
| Q3 25 | $186.9M | $125.7M | ||
| Q2 25 | $81.3M | $196.5M | ||
| Q1 25 | $237.3M | $63.8M | ||
| Q4 24 | $143.8M | $147.7M | ||
| Q3 24 | $153.8M | $98.5M | ||
| Q2 24 | $120.8M | $96.5M | ||
| Q1 24 | $111.5M | $87.6M |
| Q4 25 | $118.5M | $48.2M | ||
| Q3 25 | $171.4M | $100.1M | ||
| Q2 25 | $70.1M | $177.9M | ||
| Q1 25 | $227.2M | $51.5M | ||
| Q4 24 | $134.9M | $94.1M | ||
| Q3 24 | $141.8M | $71.8M | ||
| Q2 24 | $118.0M | $74.0M | ||
| Q1 24 | $109.2M | $65.5M |
| Q4 25 | 13.0% | 6.2% | ||
| Q3 25 | 18.9% | 14.2% | ||
| Q2 25 | 8.1% | 27.4% | ||
| Q1 25 | 24.6% | 9.1% | ||
| Q4 24 | 19.9% | 15.7% | ||
| Q3 24 | 22.3% | 13.2% | ||
| Q2 24 | 16.4% | 15.1% | ||
| Q1 24 | 14.8% | 14.8% |
| Q4 25 | 0.5% | 17.2% | ||
| Q3 25 | 1.7% | 3.6% | ||
| Q2 25 | 1.3% | 2.9% | ||
| Q1 25 | 1.1% | 2.2% | ||
| Q4 24 | 1.3% | 9.0% | ||
| Q3 24 | 1.9% | 4.9% | ||
| Q2 24 | 0.4% | 4.6% | ||
| Q1 24 | 0.3% | 5.0% |
| Q4 25 | 0.94× | 1.80× | ||
| Q3 25 | 1.27× | 1.43× | ||
| Q2 25 | 0.52× | 8.73× | ||
| Q1 25 | 1.51× | 1.80× | ||
| Q4 24 | 1.25× | 1.47× | ||
| Q3 24 | 1.33× | 1.27× | ||
| Q2 24 | 0.99× | 0.51× | ||
| Q1 24 | 0.54× | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NXT
| Transferred Over Time | $763.9M | 84% |
| Transferred At Point In Time | $145.4M | 16% |
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
